29.02.2024 15:31:59
|
CytoDyn Says FDA Lifts Hold On Leronlimab
(RTTNews) - Biotechnology company, CytoDyn Inc. (CYDY), Thursday announced that the U.S. Food and Drug Administration or FDA had lifted clinical hold on Leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications.
Following the FDA's move, the company plans to move forward with its proposed HIV clinical trial to study Leronlimab and its effects on chronic inflammation.
In the pre-market activity, CytoDyn's stock is trading at $0.1603, up 0.81 percent on the Other OTC.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!